New UK Life Sciences VC Fund Aims To Tap CRUK R&D And Accelerate Drug Development
Cancer Research UK has formed a partnership with SV Health Investors aimed at funding innovative science created from CRUK’s research network.
You may also be interested in...
Gesynta’s SEK190m ($20m) private placement allows its lead asset to enter Phase IIa studies for treating chronic inflammatory conditions in certain systemic sclerosis patients.
An expanded $120m series C financing will help Freeline advance its lead program in hemophilia B into a pivotal trial next year, CEO Theresa Heggie tells Scrip.
Novo Holdings’ REPAIR Impact Fund has opened a global ‘AMR talent contest’ to groups developing new antimicrobial treatments, offering direct investment as the prize.